Levofloxacin Tablets — Class III drug recall D-0162-2023
Terminated recall by MACLEODS PHARMA USA, INC, reported 2023-01-25, distributed nationwide. Mismatching of the embossing on the tablets (T7) with the embossing mentioned in the package insert (ML63) in
| Recall number | D-0162-2023 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | MACLEODS PHARMA USA, INC, Princeton, NJ, United States |
| Recall initiated | 2023-01-05 |
| Classified | 2023-01-17 |
| Reported by FDA | 2023-01-25 |
| Terminated | 2025-06-24 |
| Distributed | Nationwide (US) |
| Quantity | 10,052 bottles |
| NDC | 33342-0022-08 |
| Lot numbers | BLF2214A |
| Expiration dates | 2025-06 |
Product
Levofloxacin Tablets, USP 500 mg; 50-count bottles, Rx Only, Manufactured for: Macleods Pharma USA, Inc. Princeton, NJ 08540; Manufactured by: Macleods Pharmaceuticals Ltd., Baddi, Himachal Pradesh, India. NDC 33342-022-08
Reason for recall
Mismatching of the embossing on the tablets (T7) with the embossing mentioned in the package insert (ML63) in the distributed bottles.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0162-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.